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Primary T cell activation involves the integration of
three distinct signals delivered in sequence: (1) anti-
gen recognition, (2) costimulation, and (3) cytokine-
mediated differentiation and expansion. Strong im-
munostimulatory events such as immunotherapy or
infection induce profound cytokine release causing
‘‘bystander’’ T cell activation, thereby increasing
the potential for autoreactivity and need for control.
We show that during strong stimulation, a profound
suppression of primary CD4+ T-cell-mediated im-
mune responses ensued and was observed across
preclinical models and patients undergoing high-
dose interleukin-2 (IL-2) therapy. This suppression
targeted naive CD4+ but not CD8+ T cells and was
mediated through transient suppressor of cytokine
signaling-3 (SOCS3) inhibition of the STAT5b tran-
scription factor signaling pathway. These events re-
sulted in complete paralysis of primary CD4+ T cell
activation, affecting memory generation and induc-
tion of autoimmunity as well as impaired viral clear-
ance. These data highlight the critical regulation of
naive CD4+ T cells during inflammatory conditions.
INTRODUCTION
Primary T cell activation is tightly regulated and requires three
signals in sequence: signal 1, where T cell receptor (TCR) recog-
nition of cognate antigen in the context of major histocompatibil-
ity complex (MHC) restriction occurs; signal 2, involving binding
of costimulatory molecules; and signal 3, where cytokine ‘‘in-
structions’’ direct and amplify T cell differentiation and expan-240 Immunity 43, 240–250, August 18, 2015 ª2015 Elsevier Inc.sion. Lack of costimulation (signal 2) after recognition of antigen
(signal 1) has been well demonstrated to result in anergy and/or
tolerance (Jenkins and Schwartz, 1987; Schwartz, 2003). Few
studies have investigated the consequences of ‘‘out-of-order’’
signaling with regard to signal 3 on naive T cells, which can
readily occur under both acute and chronic inflammatory condi-
tions. Naive T cells tend to be refractory to cytokine signaling in
the absence of TCR engagement (Geginat et al., 2001), in part
due to decreased cytokine receptor expression compared to
their resting, antigen-experienced, memory counterparts.
Although memory T cells undergo robust proliferation and acti-
vation marker upregulation in response to signal 3 alone with
various cytokines (i.e., IL-2, IL-4, IL-6, IL-7, IL-12, IL-15, etc.),
naive T cells typically proliferate only in response to interleukin-
7 (IL-7) (Kimura et al., 2013). Despite their lack of proliferation,
some studies have revealed that naive T cells, even in the
absence of TCR engagement, can show signs of responsiveness
to cytokines through phosphorylation of signaling molecules
(Perona-Wright et al., 2010) or upregulation of certain activation
markers (Tough et al., 1999), although the ramifications from
such signaling on subsequent responses remain poorly under-
stood. Some studies suggest that local cytokine exposure during
infection might play a polarizing role on naive CD4+ T cells to-
ward a certain T helper (Th) cell subset upon subsequent co-
infection with a secondary pathogen (Perona-Wright et al.,
2010). Other studies suggest that elevated cytokine concentra-
tions might play a role in propagating the exhaustion that occurs
during chronic infections (Teijaro et al., 2013;Wilson et al., 2013).
Immune stimulatory therapies are being increasingly success-
fully applied as cancer treatments.We have previously illustrated
the induction of bystander memory CD8+ T cells and their impor-
tant role in tumor clearance in an antigen-nonspecific fashion
during treatment with systemic immunostimulatory antibodies
and cytokine-based immunotherapies (Tietze et al., 2012).
Here we have investigated the effects of systemic immune
stimulation on subsequent T cell receptor (TCR)-mediated
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Figure 1. Impaired CD4 Responses to Antigen after Systemic Inflammatory Stimuli
(A and B) Representative dot plots from (A) murine splenotypes and (B) human PBMCs before and after treatment with immunotherapy for murine cells or
systemic high-dose IL-2 for human samples. Quantification of percent memory phenotype and percent bystander are shown for each.
(C and D) Splenocytes (C) and flow-cytometry-sorted T cell populations (D) from mice that were treated as controls or with systemic immunotherapy were
harvested at day 12 of immunotherapy and stimulated ex vivo with irradiated allogeneic splenocytes (MLR) or concanavalin (Con)-A at indicated doses. Data are
shown as counts per minute (CPM).
(E) PBMCs frommetastatic melanoma patients undergoing systemic high-dose IL-2 (600,000 IU/kg i.v. bolus every 8 hr for up to 14 doses) were collected prior to
IL-2 treatment or on day 2 after IL-2 initiation and subjected to MLR or ConA stimulation at indicated doses.
(F and G) Whole splenocytes (F) or sorted naive CD4+ T cells (G) from LPS-treated mice on day 2 and subjected to MLR.
Data are representative of two to five independent experiments with two to three mice per group for murine studies or four to nine human samples for human
studies. Statistical analysis was performed by two-way ANOVA with Bonferroni’s post-test or Student’s t test where appropriate. *p < 0.05, **p < 0.01, ***p <
0.001. See also Figures S1–S4.responses. In concerted fashion, and concomitant with the
expansion of lytic bystander memory CD8+ T cells, we observe
a profound loss in the ability of treated mice to mount primary
T cell responses after systemic immunotherapy which centered
on the lack of CD4 responsiveness to TCR engagement. This
complete loss of primary T cell function in vivo also corre-
sponded with acute thymic involution. The in vivo consequences
of CD4+ T cell paralysis were considerable, leading to impaired
vaccination responses and viral clearance from lack of CD4+
T cell help. This paralysis of naive CD4+ T cells was transient,
resolving within 2 weeks of cessation of immunotherapy, and
was mediated, in part, through suppressor of cytokine
signaling-3 (SOCS3) inhibition of Janus kinase (JAK)-STAT
signaling pathways. Taken together, these studies have pro-
found implications for cytokine-based therapies for cancer and
provide insight into the functional mechanisms that can be ex-
ploited as possible interventions for the induction of impairedT cell immunity observed during periods of strong immune stim-
ulation that occur not only during cancer immunotherapy but
during sepsis and chronic viral infection as well.
RESULTS
Cytokine Pre-exposure Selectively Impairs Both Murine
and Human Primary CD4+ T Cell Immunity
High cytokine environments predominate locally during inflam-
mation as well as during periods of strong immune stimulation
that can occur during sepsis or cancer immunotherapy. We
and others have demonstrated the induction and functional sig-
nificance of cytokine-induced, antigen-nonspecific ‘‘bystander
activation’’ of memory CD8+ T cells in murine models (Figure 1A;
Tietze et al., 2012) and human patients undergoing immunosti-
mulatory therapies for cancer (Figure 1B; Tietze et al., 2012) as
well as their similar phenotype and role during viral infectionsImmunity 43, 240–250, August 18, 2015 ª2015 Elsevier Inc. 241
(Chu et al., 2013; Sckisel et al., 2014). These expanded memory
CD8+ T cells were directly activated by high cytokine concentra-
tions instead of antigen. Thus, they failed to upregulate markers
consistent with TCR engagement, such as CD25, yet expressed
other effector molecules such as NKG2D that confer the ability to
recognize and attack targets in an antigen non-specific, NK-like
fashion.We sought to investigate the effects of systemic immune
stimulation, essentially out-of-sequence signal 3, on subsequent
primary TCR-mediated responses by the naive T cell pool. The
phenotypes of memory and/or activated (CD44hi) and naive
(CD44lo) T cells in control mice and mice treated with anti-
CD40 and IL-2 immunotherapy are extensively described in Fig-
ure S1. Although there were clear differences in memory and
activated populations, naive T cell phenotypes, in both CD4+
and CD8+ T cells, were indistinguishable between control and
immunotherapy-treated groups.
Given the profound state of memory CD8+ T cell hyperactiva-
tion and the differential effects on CD4+ and CD8+ T cells that
occurred after systemic immunotherapy, we assessed how pri-
mary T cell responses to TCR-mediated stimulation might be
affected. To evaluate this, we tested mixed lymphocyte reaction
(MLR) responsiveness at the peak of immunotherapy on spleno-
cytes. A profound decrease (p < 0.001) in proliferative capacity
(Figure 1C) of the recovered T cells frommice receiving immuno-
therapy occurred. Markedly diminished T cell proliferation in
response to the mitogen Concanavalin A (ConA) (Figure 1C),
anti-CD3, and anti-CD3 and anti-CD28 (Figures S2A and S2B)
was also observed after combination immunotherapy or with
either agent (anti-CD40 or IL-2) singly (Figure S2C). This marked
T cell hyporesponsiveness was observed after systemic lipo-
polysaccharide (LPS) administration in vivo to mimic sepsis (Fig-
ures 1F and S2D). Blocking inhibitory pathways such as CTLA-4
(Figure S2E), depleting regulatory T cells (Figure S2F), adrenalec-
tomizing to reduce glucocorticoid-mediated inhibition (Fig-
ure S2G), or even in the absence of interferon (IFN)-g signaling
(Figures S2H and S2I), which we have previously shown to
rescue CD4+ T cells from activation-induced cell death (AICD)
during immunotherapy (Berner et al., 2007), did not reverse the
primary T cell hyporesponsiveness. To confirm the translatability
of this phenomenon, we assessed peripheral blood mononu-
clear cells (PBMCs) from human patients with advanced meta-
static melanoma both prior to and while undergoing high-dose
IL-2 therapy. Importantly, paralleling the murine data, profound
T cell impairmentwas also observed in thesepatients (Figure 1D),
confirming that primary response blunting occurred in both mice
and humans. These results demonstrate that global T cell activa-
tion in which bystander memory expansion occurs at the
expense of primary T cell responsiveness such that even strong
stimuli such as allogeneic responses or mitogen responses are
impaired occurs in both mouse and humans.
To confirm whether the lack of responsiveness was due to an
intrinsic T cell mechanism or the result of external factors
contributed by suppressive cell types and/or varying cell fre-
quencies, we performed the same proliferation assays on sorted
T cell populations. Sorting of splenic memory (CD44hi) and naive
(CD62L+CD44lo) T cell populations revealed that the impairment
primarily affected naive (p < 0.05) and memory (p < 0.01) CD4+
T cells (Figures 1E and 1G) but not CD8+ T cells after in vivo
immunotherapy or LPS. This effect was also mimicked in flow-242 Immunity 43, 240–250, August 18, 2015 ª2015 Elsevier Inc.based proliferation assays using BrdU incorporation as a mea-
sure of proliferation (Figure S3A). In addition to deficiencies in
proliferation, CD4+ T cells from immunotherapy-treated mice
also produced less IFN-g than CD8+ T cells (Figure S3B). Impor-
tantly, this was not due to alternative polarization patterns; CD4+
T cells from immunotherapy-treated mice also exhibited minimal
skewing toward any Th cell (Th1, Th2, Th17, Tfh, and Treg cells
were assessed by transcription factors) population upon restim-
ulation (Figure S3C). Furthermore, the minimal polarization that
was present was diminished compared to what was observed
in control treated mice (Figure S3C). Consistent with the minimal
expression of transcription factors, expression of neither IFN-g,
IL-4, nor IL-17 could be detected in these cells (data not shown)
and IL-2 expression was significantly diminished compared to
controls (Figure S3D). Importantly, supplementation of MLRs uti-
lizing sorted naive CD4+ T cells as responders with exogenous
IL-2, although it slightly improved the proliferative response,
did not fully restore the hyporesponsiveness induced by strong
immune stimulation (Figure S3E).
Because it has previously been shown that there can be a
period of stimulation refractoriness after activation that can be
partially accounted for by down-modulation of CD3, we evalu-
ated cell size and CD3 expression of memory and naive T cells
during immunotherapy. Naive CD4+ and CD8+ T cells from
immunotherapy-treated mice and humans undergoing high-
dose IL-2 were comparable in size (FSC), granularity (SSC),
CD3 expression, and CD4/8 co-receptor expression compared
to control-treated counterparts or patients prior to immuno-
therapy (Figure S4). In contrast, memory phenotype (CD44hi)
CD4+ and CD8+ T cells displayed differences in size and CD3
expression that might account for the decrease in responsive-
ness in sorted memory CD4+ T cells. Furthermore, we have pre-
viously demonstrated that memory CD4+ T cells undergo
apoptosis after immunotherapy in mice through a mechanism
of activation-induced cell death (AICD) (Berner et al., 2007),
and therefore we hypothesized that some of the underlying
mechanisms might play a role in the lack of responsiveness in
the memory CD4+ subset. The direct effect on the naive CD4+
T cell subset was unexpected and contrary to current paradigms
in which naive T cells are thought to exhibit only minimal re-
sponses to cytokine exposure in the absence of TCR binding
to cognate antigen. Therefore, we focused on the mechanisms
underlying the impairment in the naive CD4+ T cell population.
Both the systemic immunotherapy and sepsis models are hall-
marked by elevated systemic pro-inflammatory cytokines (Fig-
ures S5A and S5B). It has previously been shown that exposure
to high-dose cytokine can directly impair murine T cell activation
in vitro (Zhao et al., 2010). We therefore investigated the direct
role of cytokines in inducing hyporesponsiveness to TCR-medi-
ated stimuli after strong immune stimulation by comparing mu-
rine (Figures 2A and 2B) and human (Figures 2C and 2D) T cell
proliferative capacity in vitro after pre-incubation with IL-2.
Similar to the effects observed with T cells recovered from
treated mice in vivo, pre-exposure of sorted murine or human
naive CD4+, but not CD8+, T cells to IL-2 in vitro also resulted
in blunted responses to MLR and ConA-induced proliferation,
further suggesting that this hyporesponsiveness is a direct phys-
iological response to cytokine pre-exposure conserved across
species.
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Figure 2. Impaired CD4 Responses to
Antigen after In Vitro Pre-incubation with
Cytokine
Naive CD4+ T cells were purified by magnetic
separation from murine splenocytes (A and B) or
from human PBMCs (C and D), pre-incubated with
media or high-dose IL-2, washed, and subjected
to MLR (1:1 R:S) or ConA (1.25 mg/ml) stimulation.
Graphs with error bars indicate mean ± SEM. In
(D), bars link individual responses from a given
sample. Data are representative of two to three
independent experiments; five to seven human
samples for human studies. Statistical analysis
was performed by two-way ANOVA with Bonfer-
roni’s post-test or Student’s t test where appro-
priate. *p < 0.05, **p < 0.01, ***p < 0.001. See also
Figure S5.Naive CD4+ T Cell Impairment after Cytokine Exposure
Is Transient
The impairment of TCR-mediated proliferation in naive CD4+
T cells occurred early during treatment and became apparent
as early as day 2. Interestingly, the effect was transient; it
resolved within 2 weeks of cessation of treatment and strongly
coincided with the emergence of lytic activity in antigen-nonspe-
cific, bystander-activated memory CD8+ T cells (Figure 3A). The
transience of the effect appeared to be due to withdrawal of ther-
apy, because repeated treatment with a second course of the
regimen resulted in prolonged impairment of primary CD4+
T cell responses as assessed by MLR (Figures S5C–S5E).
PBMCs from human patients undergoing high-dose IL-2 therapy
revealedasimilar transience inMLRandmitogen responsiveness
(Figures 3B and 3C) as did our sepsis model (Figures 3D and 3E).
Given that the impaired naive CD4+ T cell responsiveness was
not permanent, we sought to determine whether the effect on
naive CD4+ T cells was truly transient or whether new thymic
output accounted for the gain back of function. We treated thy-
mectomized (ThmX) mice with immunotherapy and evaluated
MLR responses ex vivo during immunotherapy or at day 42, a
time point in which kinetic studies revealed that MLR hypores-
ponsiveness is resolved (Figure 4A). During treatment with
immunotherapy, ThmX mice were also hyporesponsive to MLR
stimulation (Figure 4B), which resolved by day 42, illustrating
restoration of naive CD4+ T cell function in the absence of thymic
output and demonstrating that the naive CD4+ T cells exposed to
therapy were capable of recovering function.
To definitively assess the duration of the naive CD4+ T cell hy-
poresponsiveness, we performed an adoptive transfer of sorted,Immunity 43, 240–250naive CD4+ T cells from TCR transgenic
mice (OT-II: OVA-specific, CD45.2+) into
congenic CD45.1 mice, treated the mice
with immunotherapy, and evaluated re-
sponses to OVA in the transferred con-
genic cells utilizing CFSE dye dilution as
a measure of proliferation (Figure 4C).
Adoptively transferred OT-II CD4+ T cells
from immunotherapy-treated mice were
profoundly impaired in response to OVA
challenge compared to control mice (p <0.001), although the two groups were indistinguishable at day
32, confirming the transient nature of the antigen-specific func-
tional deficiency (Figures 4D–4F). Thus, in contrast to permanent
anergy or tolerance, which can occur from lack of signal 2 during
T cell priming, out-of-sequence signal 3 induces a period of
short-term hyporesponsiveness, or paralysis, of naive CD4+
T cells that reverts once the inflammatory stimulus recedes if
cognate antigen is not encountered.
Naive CD4+ T Cell Paralysis Is Hallmarked by Impaired
JAK-STAT Signaling and SOCS3 Upregulation
We next sought to better understand the molecular mechanisms
underlying the naive CD4+ T cell paralysis. Because sorting ex-
periments revealed that immunotherapy-treated CD8+ T cell
populations were behaving similarly to controls upon subse-
quent stimulation through TCR, we compared the expression
of activation markers in CD4+ and CD8+ T cells after in vitro stim-
ulation after immunotherapy. Typically, in response to TCR liga-
tion, murine lymphocytes will upregulate CD44, CD25 (a compo-
nent of the high-affinity IL-2 receptor), and the inhibitory receptor
PD-1, among other acute activation markers. After ex vivo stim-
ulation with ConA (Figure 5A), both CD4+ and CD8+ T cells from
control mice exhibited robust upregulation of CD44, CD25, and
PD-1. Conversely, although CD8+ T cells from immunotherapy-
treated mice comparably upregulated all three activation
markers, CD4+ T cells expressed far less CD25 than control
counterparts (Figure 5B).
CD25 is a component of the high-affinity IL-2 receptor confer-
ring heightened sensitivity to low IL-2 concentrations (Boyman
et al., 2006). After TCR engagement, an extensive activation, August 18, 2015 ª2015 Elsevier Inc. 243
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Figure 3. Impaired Responses to TCR Stim-
ulation Recover after Cessation of Stimula-
tion
(A) Percent change of immunotherapy-treated
compared to average control at indicated time
points for CTL lytic ability at 50:1 E:T, MLR at 1:2
R:S, ConA at 5 mg/ml, anti-CD3 at 10 ng/ml, and
anti-CD3 and anti-CD28 at 10 ng/50 ng per ml.
(B and C) PBMCs from metastatic melanoma pa-
tients undergoing systemic high-dose IL-2
(600,000 IU/kg bolus every 8 hr as tolerated for a
maximum of 14 doses) were collected prior to IL-2
treatment or on days 2 and 8 after IL-2 initiation
and subjected to MLR (1:8) or ConA (2.5 mg/ml)
stimulation.
(D and E) Mice were administered LPS systemi-
cally and harvested at (D) day 2 and (E) day 7, at
which point MLRs were performed on spleno-
cytes.
All murine graphs indicate mean ± SEM. Human
data are shown as box whisker plot, bars indicate
min to max. Data are representative of at least two
independent experiments. Statistical analysis was
performed using two-way ANOVA with Bonferro-
ni’s post-test or Student’s t test where appro-
priate. *p < 0.05, **p < 0.01, ***p < 0.001. See also
Figure S6.program ensues in which several genes, including CD25 (Willer-
ford et al., 1995), are induced. Autocrine IL-2 signaling resulting
in STAT5b phosphorylation after TCR engagement is required to
stabilize the expression of CD25, allowing for complete genera-
tion of the T cell activation program (Verdeil et al., 2006). Similar
to the paralysis phenotype observed herein, T cells from
Stat5b/ mice display reduced proliferative responses to TCR
engagement as well (Moriggl et al., 1999). We hypothesized
that this pathway might be affected during immunotherapy-
induced paralysis. To investigate this, we evaluated STAT5b
phosphorylation in control and treated CD4+ T cells after
ex vivo stimulation with ConA. After stimulation, CD4+ T cells
from control mice exhibited significant (p < 0.001) phosphoryla-
tion of STAT5b and upregulation of CD25 while STAT5b phos-
phorylation and CD25 expression did not significantly differ
between unstimulated and stimulated CD4+ T cells from immu-
notherapy-treated mice. Conversely, CD8+ T cells from both
control and immunotherapy-treated mice exhibited rapid, com-
parable phosphorylation of STAT5b after ex vivo stimulation
with ConA (Figures 5C–5F).
Genetic alterations observed in the different T cell populations
via microarray analysis on the sorted T cell subpopulations re-
vealed an assortment of genes differentially expressed between
naive CD4+ and CD8+ T cells after immunotherapy (Figures 6A,
S6A, and S6B). Overall, genes associated with negative regula-244 Immunity 43, 240–250, August 18, 2015 ª2015 Elsevier Inc.tion of immune responses, negative regu-
lation of signaling, and cell death and/or
apoptosis were upregulated in CD4+
T cells whereas genes involved with im-
mune activation and proliferation were
more highly expressed in naive CD8+
T cells. Socs3 was upregulated in bothnaive and memory CD4+ but not naive or memory CD8+ T cells
after immunotherapy. JAK-STAT-dependent cytokine signaling
pathways are regulated by the suppressors of cytokine signaling
(SOCS) (Yoshimura et al., 2007) family. SOCS1, SOCS3, and CIS
have been implicated in modulation of T cell immunity and have
been shown to be induced directly by IL-2 (Palmer and Restifo,
2009), among other cytokines. We therefore validated the array
data with qPCR by evaluating the various T cell populations for
expression of Cish, Socs1, and Socs3. Cish and Socs1 expres-
sion did not vary among subsets (Figure S6C), but Socs3 was
highly upregulated in both naive and memory CD4+ T cells but
not in naive or memory CD8+ T cells (Figure 6B), mirroring the
functionality of the cells. Elevated Socs3 expression was de-
tected in naive CD4+ T cells whenever functional paralysis
occurred: after high-dose IL-2 alone (Figure S6D), in the absence
of IFN-g (Figure S6E), after adrenalectomy (Figure S6F), and after
systemic LPS (Figure 6D). The kinetics of Socs3 expression
strongly coincided with the onset of paralysis; it was detectible
by day 2 and reverted to control levels within 1 week of treatment
cessation (Figure 6C). A similar expression pattern of Socs3 in
naive CD4+ T cells was also noted after LPS exposure (Fig-
ure 6D), presumably through exposure to IL-6 induced by LPS.
Furthermore, Socs3 expression was significantly increased in
both human (Figure 6E) and murine (Figure 6F) naive CD4+
T cells after paralysis-inducing IL-2 exposure and IL-6 (Figure S7)
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Figure 4. Naive CD4 Paralysis after Strong
Immune Stimulation Is Transient
(A and B) Thymectomized mice were treated with
immunotherapy and splenocytes were harvested
and subjected to functional assays.
(A) Experimental schema.
(B) At day 11 or 42 after initiation of treatment,
splenocytes were harvested and subjected to
MLRs.
(C–F) Naive OVA-specific CD4+ T cells were flow
cytometry sorted from OT-II TCR transgenic mice
(CD45.2) and adoptively transferred into congenic
Ly5.2 (CD45.1) mice. Congenic mice were treated
with immunotherapy and adoptively transferred
naive OT-II cells were subjected to downstream
functional assays.
(C) Experimental schema.
(D–F) Representative dot plots (D) of CD4+ T cells
were purified from congenic recipients at days 12
(E) and 32 (F), stained with CFSE, and cultured in
the presence of OVA-pulsed BMDCs for 72 hr.
After 72 hr, dilution of CFSE in adoptively trans-
ferred (CD45.2) OT-II cells was assessed.
All murine bar graphs indicate mean ± SEM. Data
are representative of at least two independent
experiments. Statistical analysis was performed
by two-way ANOVA with Bonferroni’s post-test or
Student’s t test where appropriate. *p < 0.05, **p <
0.01, ***p < 0.001.exposure in vitro. Interference of Socs3, either through ex vivo
silencing of Socs3 in purified naive CD4+ T cells (Figure 6G) or
in vivo using a transgenic mouse model (Socs3fl/flcreDlck),
partially restored proliferative responses to MLR (Figure 6H),
indicating the importance of this suppressive pathway on down-
regulating naive CD4+ T cell responses after out-of-sequence
signal 3.
CD4 Paralysis Results in Impaired Memory Generation,
Viral Clearance, and Protection from Induction of
Autoimmunity In Vivo
We next evaluated the extent and immunological conse-
quences of primary CD4+ T cell paralysis resulting from out-
of-sequence signal 3 stimulation in vivo. Mice were immunized
with irradiated allogeneic splenocytes while undergoing immu-
notherapy and evaluated for secondary responses long after
immunotherapy had ended (Figure 7A). Because the immuno-
therapy regimen utilizes agonistic anti-CD40, which has been
demonstrated to bypass the need for CD4 help in the activation
of CD8+ T cells (Schoenberger et al., 1998), we included an IL-
2-alone cohort because we have observed naive CD4+ T cell
paralysis and Socs3 upregulation occur during this regimenImmunity 43, 240–250as well (Figures S2C and S6D). Strong
secondary CD4+ and CD8+ T cell re-
sponses were observed in control mice
(p < 0.001). After immunotherapy, sec-
ondary MLR responses were totally
absent whereas CD8+ T cell recall re-
sponses to allogeneic targets were com-
parable (p < 0.001), if not greater than,
control counterparts, consistent withthe role of anti-CD40 in bypassing the need for CD4+ T cell
help. In contrast, vaccination with allogeneic targets during
high-dose IL-2 administration resulted in both absent CD4+
and CD8+ T cell secondary allogeneic responses, highlighting
the profound impact of this paralysis on T cell responses overall
(Figures 7B and 7C).
We next sought a more physiologic inflammatory model to
assess the impact of the T cell paralysis. Many acute viral models
do not require CD4+ T cells to facilitate resolution of infection
(Johnson et al., 1999; Matloubian et al., 1994; Stevenson et al.,
1998). Murine cytomegalovirus (MCMV) infection has been
described to occur similarly in CD4-sufficient and -depleted
hosts with the exception of an elevated reservoir of virus in the
salivary glands of depleted hosts after 14 days of infection (Jonjic
et al., 1989). For this model, we initiated high-dose IL-2 therapy,
infected the mice with MCMV on day 2 of treatment, and evalu-
ated viral loads in the salivary glands at day 17 p.i. (Figure 7D).
NK cells were depleted in vivo prior to treatment to eliminate
any compensatory effect activated NK cells might have had on
viral loads. Mice receiving high-dose IL-2 showed reduced viral
clearance in the salivary gland (Figure 7E), comparable to that
of CD4+ T-cell-depleted control and CD4-depleted high-dose, August 18, 2015 ª2015 Elsevier Inc. 245
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Figure 5. Paralyzed CD4+ T Cells Have Impaired JAK-STAT Signaling upon Restimulation through TCR Engagement
Splenocytes from control (red) or immunotherapy (blue)-treated mice were restimulated ex vivo with ConA to mimic TCR engagement.
(A) Experimental schema.
(B) Activation marker upregulation in CD4+ and CD8+ T cells after restimulation with anti-CD3/28.
(C–F) Representative histograms (C and E) and fold change of pSTAT5b on CD4+ (D) and CD8+ (F) T cells after restimulation with ConA.
All bar graphs indicate mean ± SEM. Data are representative of three to four independent experiments with two to three mice per group. Statistical analysis was
performed by one or two-way ANOVA with Bonferroni’s post-test where appropriate. *p < 0.05, **p < 0.01, ***p < 0.001.IL-2-treated mice, indicating viral resistance impairment due to
the T cell paralysis.
One potential purpose for CD4+ T cell paralysis during sys-
temic immune activation is the protection against the induction
of autoimmunity to self-antigens. To assess this possibility, we
utilized the experimental autoimmune encephalitis (EAE) model
of multiple sclerosis, which is highly CD4+ T cell dependent in
susceptible strains. Induction of EAE was initiated on day 2 of
immunotherapy (Figure 7F) and mice were then evaluated for
the onset of EAE. It is worth noting that early symptoms of EAE
closely mimicked the symptoms of immunotherapy-related tox-
icities that occur during treatment (i.e., slowwalk or waddle, poor
tail posture, hunching, etc.). Mice receiving immunotherapy did
not develop EAE as evidenced by clinical scores that were sus-
tained around 1 (consistent with treatment-related toxicities)
whereas control mice had clinical scores averaging 3.5–4.0
(consistent with onset of EAE) (Figure 7G), providing further evi-
dence of impaired primary CD4+ T-cell-mediated immunity dur-
ing immunotherapy. Taken together, these results demonstrate
that naive CD4+ T cell paralysis induced by out-of-sequence
signal 3 not only occurs ex vivo, but can result in impaired
T-cell-mediated activation, secondary responses, and viral
clearance in vivo.
DISCUSSION
It is critical that T cell activation and expansion be tightly
controlled, particularly with CD4+ T cells in instances of strong in-
flammatory responses. This is evidenced by the ‘‘three signal’’
model of naive T cell activation. Lack of co-stimulation, or signal
2, after TCR engagement can result in anergy of naive T cells. We
now demonstrate that both human and mouse naive CD4+ but246 Immunity 43, 240–250, August 18, 2015 ª2015 Elsevier Inc.not CD8+ T cells were further regulated by exposure to cytokine
(signal 3) in the absence of TCR engagement, resulting in a tran-
sient form of anergy that we have termed paralysis. During paral-
ysis, cytokine exposure induces expression of suppressor of
cytokine signaling-3 (SOCS3), which stifles primary CD4 activa-
tion, culminating in an inability to mount CD4-dependent adap-
tive responses both in vitro and in vivo. SOCS3 represents a crit-
ical, although probably not sole, pathway in inducing the CD4+
T cell paralysis or anergy. This paralysis is transient and contin-
gent upon continued cytokine exposure of the CD4+ T cells.
Paralysis occurred rapidly within 2 days of the initiation of
treatment and was accompanied by marked acute thymic invo-
lution (data not shown). It is widely accepted that corticosterone
plays an important role in acute thymic involution and previous
studies have shown that corticosterone can induce SOCS3
expression as well (Madiehe et al., 2001). However, it appears
that corticosterone did not play a major role in paralysis because
(1) corticosterone elevation did not mimic the pattern of paralysis
in vivo, (2) adrenalectomy did not improve responsiveness of
naive CD4+ T cells despite normalization of corticosterone re-
sponses, and (3) more importantly, SOCS3 remained elevated
during adrenalectomy after immunotherapy. Nevertheless,
although it might not play a direct role in the development of
naive CD4+ T cell paralysis, thymic involution as a result of corti-
costerone elevation might potentially impact naive T cell re-
sponses through delay in the output of new naive T cells that
probably further contributes to the delay in the total recovery
of naive CD4+ T cell responses after stimulation. This would be
of particular concern in aged recipients where thymic output is
already diminished.
There appear to be fundamental differences between
CD4+ and CD8+ T cells with regard to this suppression by
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Figure 6. SOCS3 Is Elevated and Contributes to Paralyzed Phenotype of CD4+ T Cells during Strong Immune Stimulation
(A) Microarray showing clustering of genes differentially expressed in naive CD4+ and CD8+ T cells in all T cell populations.
(B) Naive and memory CD4+ and CD8+ T cell populations were sorted from splenocytes of control or immunotherapy-treated mice and fold change in SOCS3
gene expression was quantified by qPCR.
(C–F) Expression of SOCS3 in flow-cytometry-sorted naive CD4+ T cells from immunotherapy-treated (C) or LPS-treated (D) mice at indicated time points. Naive
T cells were purified from human PBMCs (E) or murine splenocytes (F) via magnetic bead separation and incubated with high-dose IL-2. At indicated time points,
Socs3 expression was quantified by qPCR (bars) and ELISA (red lines).
(G) Magnet-purified murine naive CD4+ T cells were transfected with scrambled GFP-tagged siRNA or Socs3 siRNA, incubated in high-dose IL-2, and subjected
to MLR (1:1).
(H) Purified naive CD4+ T cells from control or immunotherapy-treated SOCS3fl/fl or Socs3fl/flcreDLck mice were subjected to MLR.
All graphs indicate mean ± SEM. Data are representative of two to four independent experiments with two to threemice per group formurine studies or five human
samples for human studies. Statistical analysis was performed by one- or two-way ANOVA with Bonferroni’s post-test where appropriate. *p < 0.05, **p < 0.01,
***p < 0.001. See also Figures S6 and S7.out-of-sequence signal 3, probably due to the pivotal nature of
CD4+ T cells in orchestrating and amplifying immune responses
in general. This hints toward alternative activation and regulatory
pathways between naive CD4+ and CD8+ T cells. Indeed, micro-
array data presented herein showed global differences in gene
expression patterns. Evidence suggesting differential pheno-
type, function, and viability between activated CD4+ and CD8+
T cells after various immunostimulatory regimens exists (Berner
et al., 2007). Although differences in CD44hi CD4+ and CD8+
T cells appear to be due to IFN-g-mediated activation induced
cell death (AICD), in naive T cells this appeared to not be the
case because Ifngr1/ mice still exhibit paralysis after therapy.
CD4+ T cells represent the ideal target because conventionaldogma holds that CD4+ T cell activation is essential to productive
and sustained adaptive responses (including humoral re-
sponses). Although CD8 responses can be generated in the
absence of CD4+ T cells, it has been shown that these ‘‘helpless’’
CD8+ T cells often go on to form impaired memory (Sun and
Bevan, 2003).
The induction of the CD4+ T cells paralysis paradoxically
correlated with the expansion of ‘‘bystander’’ phenotype CD8+
T cells and non-specific lytic capacity in immunotherapy associ-
ated with successful initial anti-tumor effects. We and others
have previously shown that these bystander activated CD8+
T cells perform their function in a more ‘‘NK-like’’ fashion using
alternative receptors such as NKG2D for targeting transformedImmunity 43, 240–250, August 18, 2015 ª2015 Elsevier Inc. 247
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Figure 7. Engagement of Cognate Antigen
during Paralysis-Inducing Conditions Re-
sults in Impaired CD4 and CD8 Priming and
Memory Formation In Vivo
(A–C) BALB/c mice were treated as controls or
with immunotherapy or high-dose IL-2. On day 2 of
treatment, mice were inoculated with 10 3 106
irradiated C57BL/6 splenocytes i.p. On day 35
after treatment, splenocytes were harvested and
evaluated for functional assays.
(A) Schema of experiment.
(B) Splenocytes were harvested and subjected to
secondary MLR.
(C) CD8+ T cells were enriched from splenocytes
by magnetic bead purification and restimulated
with irradiated allogeneic splenocytes for 4 days.
On day 4, lysis of H-2b-specific targets (C1498 line)
was measured by standard 4 hr chromium-51
release assay.
(D and E) C57BL/6 mice were treated with high-
dose IL-2 and infected with murine cytomegalo-
virus (MCMV) on day 2 of treatment (D). Salivary
gland viral titers (E) as assessed by viral IE1 gene
copy number were measured on day 19 after
treatment.
(F and G) C57BL/6 mice were treated with immu-
notherapy and induction of EAE was initiated on
day 2. Mice were then monitored for onset of
neurological symptoms according to a five-point
scale (limp tail or waddling gait = 1; limp tail and
waddling gait = 2; single limb paresis and ataxia =
2.5; double limb paresis = 3; single limb paralysis
and paresis of second limb = 3.5; full paralysis of
two limbs = 4; moribund = 4.5; and death = 5).
All graphs indicate mean ± SEM. Data are repre-
sentative of one to two independent experiments
with four to six mice per group. Statistical analysis
was performed by one- or two-way ANOVA with
Bonferroni’s post-test where appropriate. *p <
0.05, **p < 0.01, ***p < 0.001.and virally infected cells rather than TCR-mediated recognition
(Chu et al., 2013; Sckisel et al., 2014; Tietze et al., 2011). Thus,
the induction of bystander memory T activation, which is driven
by cytokines and not antigen, necessitates the emergence of
another control pathway that suppresses naive CD4+ T cell
expansion even with TCR triggering resulting in paralysis of pri-
mary T cell responses. In our model we have observed that
both naive and memory CD4+ T cells undergo this paralysis.
As the cytokine milieu declines and bystander activation wanes,
so does the SOCS3-mediated suppression of the naive CD4+
T cells and restoration of primary T cell responses ensues.
The implications and practical application of these findings are
considerable. The immunotherapy regimens employed result in
successful anti-tumor effects but these data suggest that long-
term maintenance or responses to epitope-spreading will likely
be impaired. Indeed, few correlations have been uncovered link-
ing tumor-specific T cell generation and objective tumor re-
sponses with many immunotherapies (Attia et al., 2005;
Comin-Anduix et al., 2008; Maker et al., 2005; Tietze et al.,
2011). Our vaccination model suggests that although pre-exist-
ing CD8 immunity might remain intact, the development of de
novo responses to novel tumor antigens during immunotherapy248 Immunity 43, 240–250, August 18, 2015 ª2015 Elsevier Inc.might be hampered without a secondary stimulant that can
bypass the need for CD4 help, agonistic anti-CD40 in our
case. The impact on pre-existing memory CD8 responses to
the tumor is less clear. Although our data suggest that cognate
antigen recognition inmemory CD8+ T cells remains intact during
high-dose cytokine therapy, it has been shown that persistent
CD8 activation in the absence of CD4 responses (as occurs in
AIDS and other chronic infections) leads to accelerated exhaus-
tion and premature decline in immune efficacy (Appay and Row-
land-Jones, 2002; Khaitan and Unutmaz, 2011; Sachdeva et al.,
2010; Sauce et al., 2013). In addition to tumor-specific CD8+
T cells, the bystander activation of CD8+ T cells is another impor-
tant consideration that is less well understood. A recent study by
our lab suggests that bystander activation and function occurs
similarly, if not better, in CD4-depleted mice, suggesting that
CD4+ T cells are not necessary for acquisition of function (Mon-
jazeb et al., 2014). However, this study does not address the
long-term consequences of prolonged bystander activation in
the absence of CD4+ T cells to understand whether CD4+
T cells would be necessary for their maintenance as has been
shown with antigen-specific CD8+ T cells. Thus, the long-term
impact of CD4 paralysis on CD8 function (both antigen specific
and bystander) is an important avenue for future studies to
address.
We have presented data herein describing the profound
immune paralysis, particularly in the CD4+ T cell subset,
that occurs after infection or treatment exposures that lead
to supraphysiological cytokine production. However, the im-
plications for this process during physiological inflammation,
such as acute or chronic viral infections, cancer, or even ag-
ing, remain to be elucidated. Finally, the successful preven-
tion of autoimmunity in our model suggests that inducing
CD4+ T cell paralysis by pre-administering signal 3 activation
alone presents a potential viable target for inducing tolerance
in transplantation.
EXPERIMENTAL PROCEDURES
Mice
Female 8- to 12-week-old female C57BL/6 or BALB/c mice were purchased
from the animal production area at the National Cancer Institute (NCI-APA)
or The Jackson Laboratory. Congenic B6.sJL/N mice were purchased from
the NCI-APA. Foxp3-DTR mice were purchased from the Mutant Mouse
Regional Resource Center at the Jackson Laboratory. C57BL/6-IFN-g-recep-
tor (IFNgR)-KO and OT-II Tg(TcraTcrb)425Cbn (The Jackson Laboratory) mice
were bred in-house at the University of California, Davis. SOCS3fl/fl (C57BL/6
background) mice, a kind gift from Dr. Warren Alexander, were crossed to
creDLck mice (Taconic Farms) to generate Socs3fl/flcreDLck mice. All mice
were housed in the animal facilities at the University of California, Davis, under
specific-pathogen-free conditions and studies were approved by the UCDavis
Institutional Animal Care and Use committee.
Human High-Dose IL-2 Trial
Blood samples were obtained from patients with metastatic melanoma
enrolled in a randomized phase II trial and receiving high-dose IL-2 alone
as previously described (Seung et al., 2012). Patients began treatment on
a Monday (day 1) and high-dose IL-2 was administered at 600,000 IU/kg
by i.v. bolus infusion given every 8 hr for 14 planned doses depending on
how well the IL-2 was tolerated. The median number of doses in this cycle
of the study was 11. Blood samples were obtained at baseline, day 2, and
day 8. For the data shown at day 2, all patients were still undergoing therapy.
The day 8 data will vary from patient to patient depending on how many
doses they tolerated. Peripheral blood mononuclear cells (PBMCs) were cry-
opreserved from Ficoll-separated blood and stored at 170C. Signed
informed consent was obtained before enrollment. The study was approved
by the Providence Health System Regional Institutional Review Board,
Oregon.
In Vivo Antibodies and Reagents
The agonistic anti-mouse CD40 antibody (FGK115.B3) was generated as pre-
viously described (Murphy et al., 2003). Recombinant human interleukin-2
(rhIL2; Teceleukin, Roche) was provided by the National Cancer Institute
(NCI). Rat IgG (Jackson ImmunoResearch Laboratories) was used as a control
for anti-CD40. In some experiments, NK cells were depleted with 300 mg anti-
NK1.1 (PK136) grown by National Cell Culture Center. CD4+ T cells were
depleted with anti-CD4 at 500 mg (clone GK1.5, a kind gift from Garry B. Huff-
nagle, University of Michigan). LPS was purchased from Sigma. Diphtheria
toxin (Sigma) was administered at 1 mg/0.2 ml i.p. every other day beginning
at day 2.
Immunotherapeutic Regimen
Mice were administered agonistic anti-CD40 and rhIL-2 as previously
described (Berner et al., 2007). In brief, agonistic anti-CD40 or rat IgG (Jackson
Immunoresearch) was administered for 5 days (days 0–4). rhIL-2 or PBS alone
was administered twice per week for 2 weeks. For studies where the regimen
was doubled, a second round was administered identically to the first round
starting on day 14.Data Analysis and Statistics
Statistical analysis was performed with Prism software (GraphPad Software).
Data were expressed as mean ± SEM. For analysis of three or more groups,
the non-parametric ANOVA test was performed with the Bonferroni post-
test. Analysis of differences between two normally distributed test groups
was performed with the Student’s t test. Welch’s correction was applied to
Student’s t test datasets with significant differences in variance. *p < 0.05,
**p < 0.01, ***p < 0.001.
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